CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
USA - NASDAQ:CCRN - US2274831047 - Common Stock
12.16 USD
+0.57 (+4.92%)
CCRN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. While CCRN has a great health rating, its profitability is only average at the moment. CCRN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
In the past year CCRN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CCRN reported negative net income in multiple years.
CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
CCRN has a Return On Assets (-1.51%) which is comparable to the rest of the industry.
CCRN has a Return On Equity (-2.02%) which is in line with its industry peers.
With a Return On Invested Capital value of 1.44%, CCRN perfoms like the industry average, outperforming 42.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CCRN is significantly above the industry average of 9.33%.
The 3 year average ROIC (15.05%) for CCRN is well above the current ROIC(1.44%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROIC | 1.44% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
1.3 Margins
With a Operating Margin value of 0.78%, CCRN is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
CCRN's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 20.19%, CCRN perfoms like the industry average, outperforming 41.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CCRN is creating some value.
Compared to 1 year ago, CCRN has less shares outstanding
The number of shares outstanding for CCRN has been reduced compared to 5 years ago.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.81 indicates that CCRN is not in any danger for bankruptcy at the moment.
CCRN has a better Altman-Z score (4.81) than 81.00% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.81 |
ROIC/WACC0.17
WACC8.69%
2.3 Liquidity
CCRN has a Current Ratio of 3.21. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
CCRN has a Current ratio of 3.21. This is amongst the best in the industry. CCRN outperforms 85.00% of its industry peers.
A Quick Ratio of 3.21 indicates that CCRN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.21, CCRN belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -78.35% in the last year.
The Earnings Per Share has been growing by 24.57% on average over the past years. This is a very strong growth
Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -24.30% in the last year.
Measured over the past years, CCRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
3.2 Future
CCRN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.16% yearly.
The Revenue is expected to decrease by -5.63% on average over the next years.
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 57.90, which means the current valuation is very expensive for CCRN.
Compared to the rest of the industry, the Price/Earnings ratio of CCRN is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.02. CCRN is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 43.35, CCRN can be considered very expensive at the moment.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (22.57), we can say CCRN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.9 | ||
| Fwd PE | 43.35 |
4.2 Price Multiples
CCRN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CCRN is cheaper than 64.00% of the companies in the same industry.
85.00% of the companies in the same industry are more expensive than CCRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.68 | ||
| EV/EBITDA | 11.03 |
4.3 Compensation for Growth
CCRN's earnings are expected to decrease with -16.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)2.36
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
5. Dividend
5.1 Amount
No dividends for CCRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CCRN (10/13/2025, 11:36:07 AM)
12.16
+0.57 (+4.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change0%
Ins Owners5.37%
Ins Owner Change-0.41%
Market Cap398.36M
Analysts52.31
Price Target18.44 (51.64%)
Short Float %7.52%
Short Ratio6.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.4%
Min EPS beat(2)-118.38%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-39.17%
Min EPS beat(4)-118.38%
Max EPS beat(4)22.23%
EPS beat(8)4
Avg EPS beat(8)-22%
EPS beat(12)8
Avg EPS beat(12)-10.41%
EPS beat(16)12
Avg EPS beat(16)-0.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.65%
Min Revenue beat(2)-7.46%
Max Revenue beat(2)-5.84%
Revenue beat(4)0
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-7.46%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)7
Avg Revenue beat(16)0.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-52.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-54.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.9 | ||
| Fwd PE | 43.35 | ||
| P/S | 0.33 | ||
| P/FCF | 11.68 | ||
| P/OCF | 9.58 | ||
| P/B | 0.97 | ||
| P/tB | 1.66 | ||
| EV/EBITDA | 11.03 |
EPS(TTM)0.21
EY1.73%
EPS(NY)0.28
Fwd EY2.31%
FCF(TTM)1.04
FCFY8.56%
OCF(TTM)1.27
OCFY10.44%
SpS36.4
BVpS12.58
TBVpS7.31
PEG (NY)N/A
PEG (5Y)2.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROCE | 2.04% | ||
| ROIC | 1.44% | ||
| ROICexc | 1.75% | ||
| ROICexgc | 3.24% | ||
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% | ||
| FCFM | 2.86% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
ROICexc(3y)15.28%
ROICexc(5y)13.73%
ROICexgc(3y)22.9%
ROICexgc(5y)20.79%
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3Y-75.41%
ROICexcg growth 5Y-32.32%
ROICexc growth 3Y-77.25%
ROICexc growth 5Y-30.83%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score5
Asset Turnover2.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 42.39% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.74% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 | ||
| Altman-Z | 4.81 |
F-Score5
WACC8.69%
ROIC/WACC0.17
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
EBIT growth 1Y-69.02%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year540.8%
EBIT Next 3Y89.71%
EBIT Next 5YN/A
FCF growth 1Y-88.57%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-86.63%
OCF growth 3YN/A
OCF growth 5Y85.29%